EUVIMEDEUVIMED entdecken
Crossref

Nivolumab/Ipilimumab and Pembrolizumab for All Cancers: Australia's Landmark Tumor-Agnostic Immunotherapy Reimbursement

Vivek Subbiah iD, Razelle Kurzrock iD

Journal of Clinical Oncology · 10.11.2026 · 44 (32) · 3094-3098

DOI: 10.1200/jco-26-01340 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.11.2026. Verfasst von Vivek Subbiah und 1 weiteren Autor:innen. Beteiligte Einrichtung: Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA. Die Arbeit nennt 33 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA.
  • Genomic Sciences and Precision Medicine Center, and Medical College of Wisconsin Cancer Center, Milwaukee, WI.
  • WIN Consortium, Paris, France.

ORCID-Profile: Vivek Subbiah, Razelle Kurzrock

Zitieren

APA

Subbiah, V., & Kurzrock, R. (2026). Nivolumab/Ipilimumab and Pembrolizumab for All Cancers: Australia's Landmark Tumor-Agnostic Immunotherapy Reimbursement. Journal of Clinical Oncology, 44(32), 3094-3098. https://doi.org/10.1200/jco-26-01340

Vancouver

Subbiah V, Kurzrock R. Nivolumab/Ipilimumab and Pembrolizumab for All Cancers: Australia's Landmark Tumor-Agnostic Immunotherapy Reimbursement. Journal of Clinical Oncology. 2026;44(32):3094-3098. doi:10.1200/jco-26-01340

BibTeX
@article{Subbiah2026,
  author = {Subbiah, Vivek and Kurzrock, Razelle},
  title = {Nivolumab/Ipilimumab and Pembrolizumab for All Cancers: Australia's Landmark Tumor-Agnostic Immunotherapy Reimbursement},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {32},
  pages = {3094--3098},
  doi = {10.1200/jco-26-01340}
}
Kostenlos starten →